Topic: Combination Therapy with Immune Checkpoint Inhibitors for HCC

Hepatocellular carcinoma (HCC) is a primary liver cancer caused by uncontrolled hepatocyte growth and is a leading cause of cancer-related deaths worldwide. Due to its complex pathophysiology involving molecular, cellular and immune heterogeneity, there is limited knowledge of viable therapeutic options and effective regimens. The treatment of HCC requires multidisciplinary approaches and depends mainly on factors such as tumor stage, liver function, and patient response to treatment. Checkpoint inhibitors are a family of drugs that blocks specific proteins, acting as "checkpoints" to prevent the immune system from attacking cancer cells and are used to treat cancer. Checkpoint inhibitors have demonstrated potential in treating different cancer types, including HCC, and have been combined with targeted therapies or immunotherapies. As a recent advance in the treatment of HCC, they hold promise in helping the immune system combat cancer; Particularly, they may become a significant tool in the fight against this neoplastic disease, which deserves further studies.

This Special Issue welcomes original or review manuscripts, perspectives, opinions and commentaries on different aspects of HCC and its therapeutic strategies with Immune Checkpoint Inhibitors, including but not limited to:
● Epidemiology;
● Pathogenesis;
● Imaging;
● Histopathology;
● Image analysis;
● Genomics;
● Therapeutic strategies;
● Immune checkpoint inhibitors;
● Immune landscape;
● Immunotherapy;
● Innate and adaptive immune system;
● Novel biomarkers.

30 Dec 2023